What Is Semax? The Russian Peptide, the Evidence and the 2026 FDA Vote Explained

Research Guides · 14 min read · Updated October 2026

What is Semax?

If you’ve landed here, you’ve probably seen Semax described as a “Russian nootropic,” a “focus peptide” or a nasal spray that “boosts BDNF.” Some of that is grounded in published research. A lot of it stretches far past what the research shows.

Here is the plain-English version. Semax is a small synthetic peptide, a chain of seven amino acids, designed from a piece of a natural hormone called ACTH (adrenocorticotropic hormone). It was developed by Russian scientists, it is registered as a medicine in Russia, and it has been studied there for decades, mainly for stroke and other brain conditions.^[1][2]

Outside Russia, it is essentially a research compound. It has no approval from Health Canada or the US FDA,^[3][4] and its English-language evidence base is thin. That gap between “used for years in Russia” and “proven by Western standards” is the heart of the Semax story, and it’s exactly what the FDA’s advisory committee wrestled with in 2026.

Structure: an ACTH fragment with a stabilizing tail

Semax’s sequence is Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). The FDA’s 2026 briefing document gives its formula as C₃₇H₅₁N₉O₁₀S, with a molecular weight of about 814 g/mol (CAS 80714-61-0), and notes that it is also handled as an acetate salt.^[1]

Break it into two parts and the design logic becomes clear:

• Met-Glu-His-Phe is the ACTH(4–7) fragment. Short ACTH fragments in this region were studied decades ago because they seemed to affect the brain (learning and the survival of nerve cells) without ACTH’s hormonal job of telling the adrenal glands to make cortisol.^[5]
• Pro-Gly-Pro (PGP) is a tripeptide tacked onto the end. Natural ACTH fragments are broken down quickly by enzymes, and the PGP tail was added to make the molecule more stable.^[5]

You’ll see Semax described in papers as an “ACTH(4–10) analogue.” That’s because it was modelled on the longer ACTH(4–10) fragment, with the last three residues swapped for Pro-Gly-Pro.^[1][6] Both labels refer to the same molecule.

One more structural point matters for interpreting research: Semax breaks down quickly into smaller peptides. Russian researchers found that PGP itself was the main Semax-derived peptide in rat brain an hour after nasal administration, and they have suggested that some of Semax’s effects may come from these fragments rather than the intact molecule.^[5]

History: from Soviet lab to Russian pharmacy

Semax is a product of Soviet and Russian peptide science. The FDA’s review cites a synthesis route published in 1984, with Russian research papers following from the 1990s onward.^[1] Semax used in Russian clinical studies was synthesized at the Laboratory of Regulatory Peptides of the Institute of Molecular Genetics (Russian Academy of Sciences) in Moscow, and much of the published research comes from that institute, which also developed its sister peptide, Selank.^[1][7][8]

Today Semax is registered in Russia as nasal drops.^[1] The intranasal route is the one used throughout the Russian clinical literature, a historical fact about how it was developed, not a recommendation. According to a review by the Alzheimer’s Drug Discovery Foundation (ADDF), it has been used clinically in Russia for stroke, chronic cerebrovascular disease (“dyscirculatory encephalopathy”), Parkinson’s disease, optic nerve atrophy and neurological deficits in newborns.^[2] Russian researchers have also published on less obvious uses, such as peptic ulcers.^[1]

By 2018, the institute’s own researchers were describing it as “a universal drug for therapy and research” in a review covering experimental and clinical work from 1980 to 2016.^[7] That’s a confident framing. As you’ll see below, independent reviewers have been more cautious.

How Semax is thought to work

The FDA’s briefing document put it bluntly: Semax’s mechanism of action is poorly understood.^[1] What exists is a set of findings, mostly in rats and mice, that point in a few directions.

1. BDNF and other neurotrophins

This is the best-known Semax finding and the reason it’s marketed as a “BDNF peptide.” BDNF (brain-derived neurotrophic factor) is a protein that supports the survival and plasticity of neurons.

• In a 2006 rat study published in Brain Research, a single administration of Semax produced a maximal 1.4-fold increase in BDNF protein in the hippocampus, about a 1.6-fold increase in activation (phosphorylation) of its receptor, TrkB, and roughly 3-fold and 2-fold increases in BDNF and TrkB messenger RNA.^[6]
• A companion 2006 paper found specific, reversible Semax binding sites in rat basal forebrain tissue and a rapid rise in BDNF protein there three hours after nasal administration, but not in the cerebellum.^[9]
• In rats with experimentally blocked brain arteries (a stroke model), Semax increased the activity of genes for BDNF, NGF and several neurotrophin receptors in the cortex at different time points.^[5]

A 1.4-fold change in a rat hippocampus is a real, measurable effect. It is not evidence that a nasal spray “boosts BDNF” in a meaningful way in a healthy human brain.

2. Serotonin and dopamine

A 2005 study in Neurochemical Research found that in rodents, Semax raised levels of a serotonin breakdown product (5-HIAA) in the striatum. On its own, it didn’t change dopamine levels. But given before amphetamine, it markedly amplified amphetamine’s effect on dopamine release and movement.^[10] The authors framed this as positive modulation of the serotonin system. The FDA, reviewing the same body of work, flagged the amphetamine interaction as a possible abuse-potential concern that has never been properly assessed.^[1] The FDA also noted a mouse study in which a serotonin-blocking drug cancelled Semax’s pain-relieving effect, which again suggests serotonin involvement.^[1]

3. The melanocortin connection

Because Semax comes from ACTH, it belongs to the melanocortin family of peptides. Online sources often state as settled fact that it blocks specific melanocortin receptors. We couldn’t find primary data strong enough to say that confidently. What is documented is that ACTH(4–10)-type fragments have brain effects without hormonal activity,^[5] and that the exact receptor target or targets for Semax remain unclear.^[1]

4. Other findings

• Enzyme inhibition: in lab tests, Semax inhibits enkephalinases, enzymes that break down the body’s own opioid-like peptides.^[1]
• Blood clotting: rat studies report anticoagulant and antithrombotic effects. The FDA listed this as a safety concern.^[1]
• Behaviour: rodent studies describe pain-relieving, neuroprotective, antidepressant-like and anti-anxiety-like effects.^[1]

The clinical evidence, honestly

Here’s where you need to read carefully, because Semax marketing often blurs “used in Russia for years” into “clinically proven.”

Stroke: the strongest case, still weak

Stroke is where Semax has the most human data. The best summary we found is a 2018 Russian meta-analysis published in the Bulletin of Rehabilitation Medicine. Researchers searched PubMed and the Russian database eLibrary and found eight studies (654 patients) suitable for analysis. Only three of them, with 181 patients, shared the same endpoints and could be pooled.^[11]

In those pooled studies, Semax given in the acute period after stroke was associated with lower stroke-severity scores (NIHSS) at 10–14 and 21 days in moderate and severe cases, better Rankin disability scores at 21 days in the severe and moderate groups only, and better mobility scores across groups, compared with placebo.^[11] The authors’ own conclusion is the most important line: they called for a large, multicentre, double-blind trial with a standard design.^[11] That trial doesn’t appear to exist yet.

Other stroke data are harder to assess. The ADDF notes a Russian study of 110 stroke patients in which treatment raised blood BDNF levels, with higher-BDNF patients recovering better, and an earlier stroke study available only as a Russian abstract. Neither could be fully evaluated.^[2] The ADDF’s overall verdict is that Semax’s benefit in stroke may be real, but well-conducted published studies are lacking.^[2]

Cognition and focus

This is the use most people online care about, and it has the least support. The ADDF found little evidence that Semax improves cognition in healthy people and none for Alzheimer’s disease. The main healthy-volunteer study is a 24-person brain-imaging pilot that showed changes in resting brain activity, not proof of better thinking.^[2] If brain fog is what brought you here, our brain fog causes and treatment guide covers the evidence-based causes worth checking first, from sleep and thyroid to iron and medications.

Migraine, nerve pain and other uses

The FDA’s review is the most detailed independent look at the human data. It described a 1996 open-label study in which 4 of 12 migraine patients reported their headache stopping, and a trigeminal neuralgia group of 25 in which the authors themselves concluded Semax had no pain-relieving activity on its own. Other references covered healthy adults, adults with various conditions and 451 children with depression or tic disorders. Several were meeting abstracts without full details.^[1]

The FDA’s summary: small samples, no controls and insufficient reporting, so there is “insufficient evidence of effectiveness” for cerebral ischemia, migraine or trigeminal neuralgia.^[1]

What’s known about safety

“Used for decades in Russia” is often offered as proof of safety. The FDA’s review found a thinner record than that phrase suggests:^[1]

• No standard acute, repeat-dose or reproductive toxicity studies were found, and the only cancer study (in mice) was inadequately designed.
• Abuse potential has not been assessed, which matters given the amphetamine interaction above.
• The antithrombotic (anti-clotting) effects in rats raise questions for anyone with bleeding risks.
• One FDA adverse event report described eye pain and burning, with hospitalization, after use of nasal drops bought online.
• Certificates of analysis submitted for Semax lacked impurity, aggregate, endotoxin and bioburden data, so the FDA couldn’t rule out immune reactions from impurities.

The ADDF, summarizing a 2013 Russian review, reports nasal cavity discoloration in some patients and increased blood glucose in some patients with diabetes, while stressing that long-term effects and drug interactions are unknown.^[2] We go deeper in Semax side effects: what the research shows.

N-Acetyl Semax Amidate and other variants

Search for Semax and you’ll quickly hit “N-Acetyl Semax,” “Semax Amidate” and “N-Acetyl Semax Amidate” (often shortened to NASA). These are chemically modified versions of the molecule: acetylation adds a small cap to the front end of the peptide, and amidation changes the back end. Sellers market them as more stable or longer-lasting.

Here’s the honest status: we could not find peer-reviewed human studies on these variants, and essentially all of the Russian clinical literature concerns plain Semax. Claims that NASA is “stronger” or “works faster” are extrapolations from general peptide chemistry, not measured results. The FDA also flagged inconsistent naming as one reason Semax is “not well characterized” as a substance.^[1] If a product label says “Semax,” you should know exactly which molecule is in it, and a proper certificate of analysis is how you check.

Semax vs Selank in 60 seconds

Semax and Selank are often sold side by side, and they really are siblings: both come from the Institute of Molecular Genetics in Moscow, and both end in the same stabilizing Pro-Gly-Pro tail.^[1][8] But they start from different parent molecules.

For the full side-by-side, read Selank vs Semax. If anxiety is the real question for you, our anxiety treatment in Canada guide covers the approved and evidence-based options, and common Selank mistakes covers how research claims get overstated.

The July 2026 FDA panel vote on Semax

This is why Semax searches spiked this year. On July 24, 2026, the second day of a two-day meeting of the FDA’s Pharmacy Compounding Advisory Committee (PCAC), Semax and Semax acetate came up for a vote on whether they should be added to the 503A “bulks list,” the list of substances US compounding pharmacies may use.^[12]

What happened:

• FDA staff recommended against it. The FDA’s briefing concluded that Semax is not well characterized, has no documented compounding history, lacks evidence of effectiveness and has unresolved safety concerns.^[1] Both original nominations had been withdrawn, but the FDA chose to bring Semax before the committee anyway.^[13]
• The committee voted yes anyway: 8 for, 5 against, 1 abstaining.^[14] Supporters pointed to about three decades of international use and the BDNF research. Dissenters cited weak preclinical evidence, characterization problems and the risk of steering patients away from proven treatments. One member flagged possible confusion with semaxanib, an unrelated compound.^[14]
• The vote is non-binding. It doesn’t add Semax to the bulks list. The FDA must decide whether to accept the advice and then go through notice-and-comment rulemaking. Semax remains unapproved by the FDA.^[4]

The same meeting also backed BPC-157, TB-500, KPV, MOTS-c and Epitalon, and rejected DSIP. We cover the whole meeting in the 2026 FDA peptide panel vote explained.

Is Semax legal in Canada?

Short answer: there is no Health Canada-authorized Semax product, and Health Canada has named it as an unauthorized drug.

• Health Canada’s August 1, 2025 advisory on unauthorized injectable peptide drugs seized and sold in Canada lists Semax (along with Selank, BPC-157 and dozens of others). It states that injectable peptides are regulated as prescription drugs and that none of the listed products were authorized.^[3]
• Its April 9, 2026 advisory adds that “For Research Use Only” labelling doesn’t make a product legal or exempt it from the rules, and warns that unauthorized products may contain the wrong amount of active ingredient, unlisted ingredients or contaminants.^[15]

The US panel vote doesn’t change any of this. FDA compounding rules apply to US pharmacies. They are not a Health Canada authorization. If you’re interested in Semax for a medical reason, the right first step is a conversation with your doctor or pharmacist about approved options.

5 Semax myths

“Myth: Semax is a proven nootropic.”

The cognition evidence in healthy people amounts to small pilot studies. Independent reviewers at the ADDF found little evidence that it improves cognition in healthy people.^[2]

“Myth: Decades of use in Russia prove it’s safe.”

Long use is not the same as systematic safety testing. The FDA found no standard toxicity studies, an inadequate cancer study and an unassessed abuse potential.^[1]

“Myth: Semax raises BDNF in humans.”

The clearest BDNF data come from rats.^[6][9] One Russian stroke study reported higher blood BDNF in patients,^[2] but that is not the same as showing a meaningful brain BDNF increase in healthy people.

“Myth: The FDA approved Semax in 2026.”

No. An advisory committee recommended it for a compounding list, against FDA staff advice. The vote is non-binding, and Semax is not an FDA-approved drug.^[4][14]

“Myth: N-Acetyl Semax Amidate is a stronger, better-studied Semax.”

We found no peer-reviewed human research on NASA. The clinical literature is on plain Semax.

For researchers

TrueLabs supplies Semax from $41 and Selank from $40 for in vitro and laboratory research, such as neurotrophin expression in cell culture, peptide stability and degradation studies, or comparisons of PGP-tailed analogues. Given the FDA’s point that Semax is poorly characterized,^[1] verifying identity and purity matters more than usual: see how to read a peptide COA, check the COA library and review how to store peptides.

See Semax →

FAQ

Related reading

• Selank vs Semax
• Semax Side Effects
• The 2026 FDA Peptide Panel Vote
• Brain Fog: Causes and Treatment
• Anxiety Treatment in Canada
• Peptides 101

References

1. US Food and Drug Administration. FDA briefing document: Semax (free base) and Semax acetate, Pharmacy Compounding Advisory Committee meeting July 23–24, 2026 (review memo dated May 11, 2026). FDA
2. Alzheimer’s Drug Discovery Foundation. Cognitive Vitality for Researchers: Semax. ADDF
3. Health Canada. Unauthorized injectable peptide drugs seized and sold in Canada may pose serious health risks. August 1, 2025. Recalls and Safety Alerts
4. FDA panel backs 6 peptides for compounding. AJMC. July 31, 2026. AJMC
5. Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010;30(1):71-79. PubMed
6. Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. PubMed
7. Koroleva SV, Myasoedov NF. Semax as a universal drug for therapy and research. Biology Bulletin. 2018;45(6):589-600. Journal page
8. Selank. Wikipedia (sequence, origin as a tuftsin analogue, and developer). Wikipedia
9. Dolotov OV, Karpenko EA, Seredenina TS, Inozemtseva LS, Levitskaya NG, Zolotarev YA, Kamensky AA, Grivennikov IA, Engele J, Myasoedov NF. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006;97(Suppl 1):82-86. PubMed
10. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. DOI
11. Shmonin AA, Verbickaya EV, Soloveva LN, Malceva MN, Melnikova EV. Meta-analysis: Semax effectiveness in the acute period of stroke. Bulletin of Rehabilitation Medicine. 2018;2(84). Journal
12. US Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting agenda, July 23–24, 2026. FDA
13. US Food and Drug Administration. FDA briefing document: Pharmacy Compounding Advisory Committee, July 23–24, 2026 (overview of nominated bulk drug substances). FDA
14. The PEPTIDE-L wave rolls on! PCAC adds two more bulk drug substances for the 503A list. FDA Law Blog. July 28, 2026. FDA Law Blog
15. Health Canada. Think twice before injecting peptides bought online: Unauthorized products can seriously harm your health (RA-81874). April 9, 2026. Recalls and Safety Alerts

This article summarizes published research and regulatory information for information only and is not medical advice. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.